Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1997 2
1998 3
1999 1
2000 1
2001 2
2002 1
2003 2
2004 2
2005 3
2006 3
2007 3
2008 1
2009 1
2010 3
2011 5
2012 5
2013 1
2014 5
2015 6
2016 4
2017 11
2018 16
2019 15
2020 10
2021 6
2022 9
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31270154

116 results

Results by year

Filters applied: . Clear all
Page 1
A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Pillarisetti K, Edavettal S, Mendonça M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F. Pillarisetti K, et al. Blood. 2020 Apr 9;135(15):1232-1243. doi: 10.1182/blood.2019003342. Blood. 2020. PMID: 32040549 Free PMC article. Clinical Trial.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ. Smith EL, et al. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. doi: 10.1126/scitranslmed.aau7746. Sci Transl Med. 2019. PMID: 30918115 Free PMC article.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Chari A, et al. N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10. N Engl J Med. 2022. PMID: 36507686 Clinical Trial.
[Bispecific antibodies in multiple myeloma].
Escure G, Manier S. Escure G, et al. Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003. Bull Cancer. 2021. PMID: 34920804 Review. French.
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, McElroy PL, Canon J, Desjarlais JR, Coxon A, Balazs M, Nolan-Stevaux O. Zuch de Zafra CL, et al. Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27. Clin Cancer Res. 2019. PMID: 30918018
116 results